2011

February 09, 2011 - Cephalon, Inc. (Nasdaq: CEPH) and Alba Therapeutics Corporation, today announced that the companies have signed an agreement providing Cephalon with an option to purchase all of Alba’s assets relating to larazotide acetate, a tight junction modulator, progressing toward a Phase IIb clinical trial for the treatment of celiac disease.

March 17, 2009 - Alba Therapeutics Corporation announced today it will initiate further clinical studies for patients diagnosed with celiac disease with their lead compound, larazotide acetate.

2008

November 11, 2008 - Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease

October 7, 2008 - Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting

October 2, 2008 - Alba Therapeutics Announces Promotions

May 20, 2008 - Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference

May 16, 2008 - Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease

April 3, 2008 - Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer

March 18, 2008 - Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award

January 18, 2008 - Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management